Pediatric multisystem inflammatory syndrome associated with a new coronavirus infection: unresolved issues

Since March 2020, the first reports have appeared about the increasing, almost everywhere, number of children who have undergone a new coronovirus infection caused by SARS-Cov-2 with a symptom complex resembling the manifestations of Kawasaki disease. A special feature of the clinical manifestations of this syndrome, which is called “Pediatric multisystem inflammatory syndrome associated with COVID-19”, is the high incidence of life-threatening conditions caused by the sharp development of arterial hypotension against the background of cardiogenic or vasogenic shock.
In St. Petersburg, since the end of November 2020, there has been a sharp surge in admissions of children to the ICU of various hospitals with the clinic of Pediatric multisystem inflammatory syndrome, who have laboratory confirmation of the transferred COVID-19.
The purpose of this article is to attract the attention of doctors of various profiles, to combine efforts to study this pathology, to determine the criteria for verifying the diagnosis, optimal treatment regimens and dispensary monitoring of patients who have been ill.

1. Royal College of Paediatric and Child Health. Guidance: paediatric multisystem inflammatory syndrome temporally associated with COVID-19. https://www.rcpch.ac.uk/resources/guidance-paediatric-multisystem-inflammatory-syndrometemporally-associated-covid-19. Published 2020.

2. Kelvin, Alyson A., and Scott Halperin. “COVID-19 in children: the link in the transmission chain.” The Lancet Infectious Diseases 20.6 (2020): 633-634.

3. Leidman, Eva, et al. “COVID-19 trends among persons aged 0–24 years—united states, march 1–december 12, 2020.” Morbidity and Mortality Weekly Report 70.3 (2021): 88.14]

4. Toubiana J, Poirault C, Corsia A, Bajolle F, Fourgeaud J, Angoulvant F, et al. Kawasaki-like multisystem inflamяmatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study. BMJ. 2020; 369: m2094.

5. Ravelli A, Minoia F, Davì S, Horne A, Bovis F, Pistorio A, et al. 2016 Classification Criteria for Macrophage ActivationSyndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann. Rheum. Dis. 2016;75 (3): 481–489.

6. L.V. Bregel`, M.M. Kostik, L.Z. Fell`, O.S. Efremova, M.K. Soboleva, T.S. Krupskaya, A.E. Matyunova. Bolezn` Kavasaki i mul`tisistemny`j vospalitel`ny`j sindrom pri infekcii COVID-19 u detej. Pediatriya im. G.N. Speranskogo. 2020; 99 (6): 209–219.

7. Consiglio, Camila Rosat, et al. «The immunology of multisystem inflammatory syndrome in children with COVID-19.» Cell 183.4 (2020): 968-981.

8. Verdoni L, Mazza A, Gervasoni A. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARSCoV-2 epidemic: an observational cohort study. Lancet. 2020; 395 (10239): 1771–1778.

9. Daskalakis D. Health Alert# 13: pediatric multi-system inflammatory syndrome potentially associated with COVID-19 //NYC Health. – 2020. [Internet] URL: https://www1.nyc.gov/assets/doh/downloads/pdf/han/alert/2020/covid-19-pediatric-multi-system-inflammatory-syndrome.pdf (data available 24.01.2021)

10. Ahmed, Mubbasheer, et al. «Multisystem inflammatory syndrome in children: A systematic review.» EClinicalMedicine 26 (2020): 100527.1, 16

11. Osobennosti klinicheskix proyavlenij i lecheniya zabolevaniya, vy`zvannogo novoj koronavirusnoj infekciej (COVID-19), u detej. Metodicheskie rekomendacii. Versiya 2 / Aleksandrovich Yu.S., Alekseeva E.I., Bakradze M.D. i dr. // Pediatricheskaya farmakologiya. 2020; 17 (3): 187–212. doi: 10.15690/pf.v17i3.2123; Available from: https://stati0.minzdrav.gov.ru/system/attachments/attaches/000/050/914/original/03062020_deti_COVID-19_v2.pdf

12. Jindal AK, Pilania RK, Prithvi A, Guleria S, Singh S. Kawasaki disease: characteristics, diagnosis, and unusual presentations. Expert. Rev. Clin. Immunol. 2019; 15 (10): 1089–1104

13. Whittaker E, Bamford A, Kenny J. Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARSCoV-2. JAMA. 2020; 324 (3): 259–269.

14. Wu L, O›Kane AM, Peng H, Bi Y, Motriuk-Smith D, Ren J. SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management. Biochem. Pharmacol. 2020; 178: 114114

15. Cuomo A.M., Zucker H.A., Dreslin S. Health advisory: pediatric multi-system inflammatory syndrome potentially associated with soronavirus disease (COVID-19) children //New York State of Opportunity. Department of Health. – 2020. [Internet] https://www.health.ny.gov/press/releases/2020/docs/2020-05-06_covid19_pediatric_inflammatory_syndrome.pdf (data available 24.01.2021)

16. Kawasaki T. Kawasaki disease. Proc Jpn Acad Ser B Phys Biol Sci. 2006 Apr;82(2):59-71.

17. Kawasaki T. Kawasaki disease. Int J Rheum Dis. 2014 Jun;17(5):597-600. doi: 10.1111/1756-185X.12408.